



**Clinical Research Active Trials – Open to Patient Enrollment**

23April 2018

Cancer Type	Trial Name	Sponsor	Site	Norwalk IRB #
<b>Breast</b>	<b>A011202:</b> A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive sentinel Lymph Node Disease after Neoadjuvant Chemotherapy	Alliance	N	15-02
	<b>SWOG 1416:</b> Phase II Randomized Placebo-controlled Trial of Cisplatin with or without ABT-888 (veliparib) in Metastatic Triple -Negative Breast Cancer and /or BRCA Mutation Associated Breast Cancer	SWOG	D/NM	CIRB
	<b>EA1131:</b> A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy	ECOG-ACRIN	D/NM	CIRB
	<b>POLARIS A5481082</b> Palbociclib (IBRANCE®) in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study	Pfizer	N/D/NM	16-22 Shulman
	<b>WO39392:</b> A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WITH PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH PRIMARY INVASIVE TRIPLE-NEGATIVE BREAST CANCER	F. Hoffmann-La Roche Ltd	N	CGIRB
	<b>IMMU-132-05:</b> An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments	Immunomedics	N	WIRB



**Clinical Research Active Trials – Open to Patient Enrollment**

23April 2018

<b>GI</b>	<b>N1048:</b> A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	Alliance	N	12-14
	<b>PCYC-1128-CA:</b> A Phase1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors	Pharmacyclics	N	16-12
<b>GU</b>	<b>WO30070</b> - A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) As Monotherapy And In Combination With Platinum-Based Chemotherapy In Patients With Untreated Locally Advanced Or Metastatic Urothelial Carcinoma	Genentech	N/D/NM	17-06
	<b>S1605</b> - PHASE II TRIAL OF ATEZOLIZUMAB IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER	SWOG	D/NM	CIRB
	<b>A031501</b> - PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION	Alliance	D/NM	CIRB
<b>Lung-NSCLC</b>	<b>A151216:</b> Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial	Alliance	D/NM	CIRB



**Clinical Research Active Trials – Open to Patient Enrollment**

23April 2018

<b>Lung-NSCLC</b>	<b>A081105:</b> Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer	Alliance	D/NM	CIRB
	<b>E4512:</b> A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein	ECOG-ACRIN	D/NM	CIRB
	<b>EA5142:</b> Adjuvant Nivolumab in Resected Lung Cancers (ANVIL): A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Cancers	ECOG-ACRIN	D/NM	CIRB
	<b>D5164C00001</b> A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIa Non-small Cell Lung Carcinoma, following Complete Tumor Resection With or Without Adjuvant Chemotherapy ( <b>ADAURA</b> )	Astra Zeneca	N	16-01
<b>Lymphoma</b>	<b>Celgene Magnify:</b> A phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma	Celgene	N/D/NM	14-07 16-14
<b>GYN</b>	<b>GOG 0225:</b> Can Diet And Exercise Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?	GOG	D/NM	N/A
	<b>YO39523:</b> A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	GOG	D/NM	17-09



**Clinical Research Active Trials – Open to Patient Enrollment**

23April 2018

<b>Multiple Myeloma</b>	<b>RareCyte Technology:</b> Detection and Enumeration of Circulating Plasma Cells in Patients with MGUS and Myeloma using RareCyte Technology	Fiedler	D/NM	N/A
<b>Myelofibrosis</b>	<b>INCB 39110-209:</b> An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis	Incyte Corporation	N/D/NM	17-19
<b>Pancreatic</b>	The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer	Frank	N/D/NM	15-10
	Pre- and Post-Surgical Molecular Testing in Individuals with Operable Pancreatic Cancer	Frank, Kleiner, Martignetti	N/D/NM	16-15
	A Pancreatic Cancer Screening Study in High Risk Individuals	Frank	N/D/NM	16-17
	A Pancreatic Screening Study in Individuals with New-Onset Diabetes Mellitus	Frank	N/D/NM	18-01
	<b>CanStem111P:</b> A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.	Boston BioMedical	N/D/NM	17-05



**Clinical Research Active Trials – Open to Patient Enrollment**

23April 2018

<b>Translational</b>	Serum-based Signature of Activation of the PD-1/PD-L1 Pathway in Patients with Cancer. Serial serum samples from patients starting immune-based therapies that target the PD-1/PDL-1 pathway in cancer patients.	Frank	N/D/NM	15-35
	<b>BB001:</b> The Western Connecticut Health Network (WCHN), Danbury and Norwalk Hospitals Biobank - A Collection of Biospecimens and Clinical Data to Facilitate Research ( <b>GYN Biobank</b> )	WCHN	N/D	CIRB
<b>Pending</b>	<b>B9991023:</b> A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES	Pfizer	N	WIRB
	<b>CA2099NC / INCB24360-309A :</b> Phase 3, Randomized, Global Trial of Nivolumab and Epcadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Incyte Corporation/Bristol-Myers Squibb Research and Development	N/D/NM	WIRB
	<b>SGNLVA-001:</b> A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer	Seattle Genetics, Inc.	N	WIRB
	<b>SGNLVA-002:</b> Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer	Seattle Genetics, Inc.	N	WIRB